+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Infectious Disease Diagnostic Market - Global Forecast 2026-2032- Product Image
Infectious Disease Diagnostic Market - Global Forecast 2026-2032- Product Image
Sale

Infectious Disease Diagnostic Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4829907
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Infectious Disease Diagnostic Market is projected to reach USD 29.41 Billion in 2026. It is expected to continue growing at a CAGR of 8.93%, reaching USD 49.28 Billion by 2032.

Infectious disease diagnostics form the clinical and public health backbone for detecting, confirming, monitoring, and controlling communicable diseases. The market spans molecular diagnostics, immunoassays, rapid antigen tests, culture-based microbiology, antimicrobial susceptibility testing, sequencing, syndromic panels, and point-of-care testing used across hospitals, reference laboratories, public health agencies, and decentralized care settings.

Demand remains anchored in measurable disease burden. WHO reported 10.8 million tuberculosis cases in 2023 and an estimated 263 million malaria cases in 2023; UNAIDS reported nearly 40 million people living with HIV in 2024; and antimicrobial resistance was associated with 1.27 million attributable deaths in 2019. These realities continue to prioritize accurate, fast, and scalable infectious disease testing that supports timely treatment, outbreak containment, and evidence-based surveillance.

Transformative Shifts in Infectious Disease Diagnostics

The infectious disease diagnostic landscape is shifting from centralized, single-pathogen testing toward faster, multiplexed, and decentralized models. PCR and other nucleic acid amplification tests remain essential for high-sensitivity detection, while rapid antigen, lateral flow, and near-patient molecular platforms are expanding access where turnaround time directly affects isolation, treatment, antimicrobial selection, and outbreak control.

Public health surveillance is also becoming more integrated with clinical diagnostics. Wastewater monitoring, genomic sequencing, antimicrobial susceptibility testing, and electronic laboratory reporting are increasingly linked to preparedness programs. At the same time, IVDR implementation in Europe, FDA oversight in the United States, and quality requirements for laboratory-developed tests are raising expectations for analytical validation, traceability, clinical evidence, and post-market performance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming an enabling layer across infectious disease diagnostics rather than a standalone replacement for laboratory science. AI-supported image analysis can assist digital microscopy, colony recognition, and radiology triage, while machine learning models can prioritize sepsis risk, optimize antimicrobial stewardship, flag abnormal laboratory patterns, and support outbreak forecasting when connected to validated clinical and epidemiological data.

The cumulative impact is faster decision support, improved laboratory workflow, and stronger population-level surveillance. However, adoption depends on transparent validation, representative datasets, cybersecurity, interoperability, bias monitoring, and clinician oversight. Industry leaders that combine AI with regulatory-grade evidence, laboratory information systems, and explainable outputs will be better positioned to convert automation into trusted diagnostic value.

Regional Dynamics Across Infectious Disease Diagnostics

Asia-Pacific is a high-priority infectious disease diagnostics region due to large population scale, persistent TB, dengue, hepatitis, malaria, and respiratory infection burden, and expanding molecular testing capacity in China, India, Japan, South Korea, Australia, and ASEAN countries. WHO has consistently identified South-East Asia and the Western Pacific as central regions for tuberculosis and arboviral disease surveillance, supporting continued demand for rapid diagnostic tests, molecular assays, and public health laboratory strengthening.

North America remains a technology leader, supported by CLIA-certified laboratories, FDA-cleared diagnostic platforms, CDC surveillance networks, strong laboratory quality systems, and rapid uptake of syndromic and molecular testing for respiratory pathogens, sexually transmitted infections, sepsis, and healthcare-associated infections. Latin America faces recurring dengue, Zika, chikungunya, TB, HIV, and respiratory disease pressures, driving demand for affordable rapid tests, decentralized sample collection, and regional reference laboratory capacity.

Europe is shaped by strong public health systems, antimicrobial resistance programs, cross-border disease surveillance, and EU IVDR compliance, with laboratories prioritizing validated assays, traceability, and quality management. The Middle East is investing in laboratory modernization and preparedness linked to international travel, migration, and mass-gathering risks, while Africa remains central to global diagnostic access priorities for HIV, TB, malaria, cholera, viral hemorrhagic fevers, and outbreak-prone pathogens.

Strategic Group Insights for Infectious Disease Testing

ASEAN demand is influenced by dengue seasonality, TB control, respiratory infections, cross-border mobility, and the need for scalable point-of-care diagnostics across island, rural, and high-density urban health systems. The region’s public health priorities support rapid antigen testing, molecular confirmation, laboratory networking, and digital reporting for diseases with epidemic potential.

GCC countries are advancing laboratory automation, molecular diagnostics, and biosurveillance through hospital investment, public health modernization, and preparedness for travel-associated infections and mass-gathering events. The European Union is defined by harmonized regulatory expectations under IVDR, ECDC-led surveillance coordination, antimicrobial resistance strategies, and laboratory quality requirements that favor clinically validated and traceable diagnostic solutions.

BRICS countries combine high infectious disease burden with expanding diagnostic infrastructure, domestic manufacturing capacity, and public health programs focused on TB, HIV, hepatitis, malaria, respiratory infections, and antimicrobial resistance. G7 markets lead in R&D funding, reimbursement depth, pandemic preparedness, genomic surveillance, and advanced laboratory automation, while NATO members increasingly view infectious disease diagnostics as part of biosecurity, resilience, and civilian-military health preparedness.

Country-Level Insights Shaping Diagnostic Demand

The United States leads in molecular diagnostics adoption, public health reporting, laboratory-developed testing capacity, and FDA-regulated innovation, while Canada emphasizes coordinated provincial laboratory networks, antimicrobial resistance monitoring, and respiratory virus surveillance. Mexico and Brazil show strong demand for affordable infectious disease testing across dengue, TB, HIV, hepatitis, and respiratory pathogens, with Brazil also benefiting from established public health institutes, surveillance experience, and local production capabilities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are shaped by public reimbursement, hospital laboratory consolidation, antimicrobial resistance programs, respiratory surveillance, and IVDR transition planning, while Russia maintains demand across TB, viral hepatitis, HIV, and respiratory testing. These countries continue to prioritize diagnostic quality, laboratory automation, and validated molecular and immunoassay platforms aligned with national health systems.

China and India represent large-scale diagnostic priorities due to population size, domestic manufacturing, expanding hospital networks, and significant infectious disease burden, including TB, viral hepatitis, dengue, respiratory infections, and antimicrobial resistance concerns. Japan, Australia, and South Korea are advanced diagnostic markets with strong quality systems, aging populations, high uptake of automated molecular and syndromic testing, and active surveillance for influenza, COVID-19, antimicrobial resistance, and emerging pathogens.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize validated, high-throughput molecular platforms, rapid point-of-care formats, antimicrobial susceptibility tools, and multiplex panels that address respiratory infections, sexually transmitted infections, sepsis, TB, HIV, hepatitis, malaria, dengue, and antimicrobial resistance. Product strategies should align with clinical workflows, reimbursement evidence, sample-to-answer usability, quality control, connectivity, and total cost of ownership.

Organizations should also invest in regional manufacturing resilience, regulatory readiness, and data connectivity. Partnerships with public health agencies, hospitals, non-governmental organizations, and reference laboratories can accelerate adoption in underserved regions. AI capabilities should be embedded only where they improve accuracy, turnaround time, workflow efficiency, antimicrobial stewardship, or surveillance value and are supported by auditable clinical evidence.

Research Methodology

The research methodology is built from verified secondary research and data triangulation across public health, regulatory, and scientific sources, including WHO, CDC, ECDC, FDA, UNAIDS, national health agencies, peer-reviewed literature, and major infectious disease surveillance reports. Disease burden, regulatory direction, diagnostic workflow, technology adoption patterns, and public health priorities were assessed to identify durable industry drivers.

The methodology emphasizes evidence-based interpretation rather than speculative forecasting. Insights were validated through cross-source comparison, with attention to disease prevalence, diagnostic performance, laboratory infrastructure, regulatory controls, regional healthcare capacity, procurement dynamics, and surveillance needs. Conclusions were framed to support strategic planning for diagnostic manufacturers, laboratories, healthcare providers, investors, public health organizations, and policymakers.

Conclusion

Infectious disease diagnostics are moving into a new era defined by speed, decentralization, genomic intelligence, antimicrobial resistance monitoring, and connected surveillance. Persistent global burdens from TB, malaria, HIV, respiratory viruses, dengue, hepatitis, healthcare-associated infections, and drug-resistant pathogens ensure that accurate testing remains essential to both individual care and public health security.

The strongest industry positions will belong to organizations that combine scientific validity, regulatory compliance, scalable access, workflow integration, and digital connectivity. As healthcare systems prepare for endemic threats and future outbreaks, diagnostics will continue to serve as the first line of detection, the guide for targeted treatment, and the foundation for evidence-based infectious disease control.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Infectious Disease Diagnostic Market, by Product
7.1. Introduction
7.2. Instruments
7.2.1. Immunoassay Analyzers
7.2.2. Mass Spectrometers
7.2.3. Microarrays
7.2.4. PCR Systems
7.3. Reagents & Kits
7.3.1. Antigen Detection Kits
7.3.2. ELISA Kits
7.3.3. Immunoassay Kits
7.3.4. PCR Kits
7.4. Software
8. Infectious Disease Diagnostic Market, by Sample Type
8.1. Introduction
8.2. Blood
8.3. Stool
8.4. Swab
8.4.1. Nasal
8.4.2. Rectal
8.4.3. Throat
8.5. Urine
9. Infectious Disease Diagnostic Market, by Testing Type
9.1. Introduction
9.2. Laboratory Testing
9.3. PoC Testing
10. Infectious Disease Diagnostic Market, by Pathogen Type
10.1. Introduction
10.2. Bacterial
10.3. Fungal
10.4. Parasitic
10.5. Viral
10.5.1. Hepatitis
10.5.2. HIV
10.5.3. Influenza
11. Infectious Disease Diagnostic Market, by Disease Type
11.1. Introduction
11.2. Bacterial Infectious Diseases
11.2.1. Meningitis
11.2.2. Pneumonia
11.2.3. Tuberculosis
11.3. Fungal Infections
11.3.1. Aspergillosis
11.3.2. Candidiasis
11.3.3. Cryptococcosis
11.4. Parasitic Infections
11.4.1. Leishmaniasis
11.4.2. Malaria
11.4.3. Schistosomiasis
11.5. Vector-borne Infections
11.5.1. Dengue Fever
11.5.2. Lyme Disease
11.5.3. Zika Virus
11.6. Viral Infectious Diseases
11.6.1. Hepatitis (A, B, C)
11.6.2. Hepatitis B & C
11.6.3. HIV/AIDS
11.6.4. Influenza
12. Infectious Disease Diagnostic Market, by End-User
12.1. Introduction
12.2. Academic & Research Institutes
12.3. Diagnostic Laboratories
12.4. Hospitals & Clinics
13. Infectious Disease Diagnostic Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Africa
13.5. Latin America
13.6. Middle East
14. Infectious Disease Diagnostic Market, by Group
14.1. NATO
14.2. G7
14.3. European Union
14.4. BRICS
14.5. ASEAN
14.6. GCC
15. Infectious Disease Diagnostic Market, by Country
15.1. United States
15.2. China
15.3. Germany
15.4. Japan
15.5. India
15.6. United Kingdom
15.7. France
15.8. Italy
15.9. Canada
15.10. Australia
15.11. Russia
15.12. Brazil
15.13. South Korea
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. Adaptive Biotechnologies Corporation
17.3. Agilent Technologies, Inc.
17.4. Becton, Dickinson and Company
17.5. Bio-Rad Laboratories, Inc.
17.6. Bio-Techne Corporation
17.7. bioMérieux SA
17.8. Boston Scientific Corporation
17.9. Bruker Corporation
17.10. Cardinal Health Inc.
17.11. Danaher Corporation
17.12. F. Hoffmann-La Roche Ltd.
17.13. GE HealthCare Technologies Inc.
17.14. Grifols, S.A.
17.15. Hologic Inc.
17.16. Illumina, Inc.
17.17. Johnson & Johnson Services Inc.
17.18. Konica Minolta, Inc.
17.19. Koninklijke Philips N.V.
17.20. MedMira Inc.
17.21. Medtronic PLC
17.22. Merck KGaA
17.23. Olympus Corporation
17.24. Perkin Elmer, Inc.
17.25. Pfizer Inc.
17.26. Qiagen N.V.
17.27. Quest Diagnostics Incorporated
17.28. Siemens Healthineers AG
17.29. Sysmex Corporation
17.30. Thermo Fisher Scientific, Inc.
17.31. Trivitron Healthcare
List of Figures
FIGURE 1. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MASS SPECTROMETERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MASS SPECTROMETERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MASS SPECTROMETERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL MICROARRAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL MICROARRAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL MICROARRAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PCR SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PCR SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PCR SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ANTIGEN DETECTION KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ANTIGEN DETECTION KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ANTIGEN DETECTION KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ELISA KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ELISA KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ELISA KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL IMMUNOASSAY KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL IMMUNOASSAY KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL IMMUNOASSAY KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PCR KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PCR KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL PCR KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL STOOL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL STOOL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL STOOL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SWAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SWAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SWAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL NASAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL NASAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL RECTAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL RECTAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL RECTAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL THROAT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL THROAT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL THROAT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL URINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL URINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL LABORATORY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL LABORATORY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL LABORATORY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL POC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL POC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL POC TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL FUNGAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL FUNGAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL FUNGAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL PARASITIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL PARASITIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PARASITIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL VIRAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HEPATITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HEPATITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HEPATITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HIV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HIV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HIV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL BACTERIAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL BACTERIAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL BACTERIAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL MENINGITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL MENINGITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL MENINGITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL PNEUMONIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL PNEUMONIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL PNEUMONIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL TUBERCULOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL TUBERCULOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ASPERGILLOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL ASPERGILLOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL ASPERGILLOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL CANDIDIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL CANDIDIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL CANDIDIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL LEISHMANIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL LEISHMANIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL LEISHMANIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL MALARIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL MALARIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL MALARIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL SCHISTOSOMIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL SCHISTOSOMIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL SCHISTOSOMIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL VECTOR-BORNE INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL VECTOR-BORNE INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL VECTOR-BORNE INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL DENGUE FEVER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL DENGUE FEVER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL DENGUE FEVER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL LYME DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL LYME DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL LYME DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL ZIKA VIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL ZIKA VIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL ZIKA VIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL VIRAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL VIRAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL VIRAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL HEPATITIS (A, B, C) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL HEPATITIS (A, B, C) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL HEPATITIS (A, B, C) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL HEPATITIS B & C MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL HEPATITIS B & C MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL HEPATITIS B & C MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL HIV/AIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL HIV/AIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL HIV/AIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2017-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2017-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 179. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 180. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 181. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 182. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 183. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 184. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 185. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 186. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 187. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 188. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 189. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 190. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 191. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2017-2032 (USD MILLION)
TABLE 192. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2017-2032 (USD MILLION)
TABLE 193. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 194. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 195. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 196. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 197. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 198. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 199. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 200. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 201. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 202. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 203. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 204. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 205. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 206. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 207. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2017-2032 (USD MILLION)
TABLE 208. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2017-2032 (USD MILLION)
TABLE 209. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 210. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 211. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 212. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 213. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 214. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 215. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 216. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 217. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 218. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 219. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 220. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 221. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 222. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 223. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2017-2032 (USD MILLION)
TABLE 224. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2017-2032 (USD MILLION)
TABLE 225. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 226. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 227. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 228. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 229. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 230. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 231. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 232. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 233. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 234. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 235. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 236. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 237. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 238. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 239. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2017-2032 (USD MILLION)
TABLE 240. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2017-2032 (USD MILLION)
TABLE 241. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 242. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 243. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 244. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 245. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 246. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 247. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 248. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 249. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 250. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 251. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 252. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 253. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 254. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 255. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2017-2032 (USD MILLION)
TABLE 256. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2017-2032 (USD MILLION)
TABLE 257. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 258. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 259. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 260. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 261. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 262. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 263. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 264. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 265. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 266. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 267. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 268. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 269. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 270. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 271. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 272. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2017-2032 (USD MILLION)
TABLE 273. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2017-2032 (USD MILLION)
TABLE 274. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 275. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 276. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 277. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 278. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 279. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 280. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 281. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 282. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 283. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 284. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 285. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 286. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 287. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 288. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2017-2032 (USD MILLION)
TABLE 289. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2017-2032 (USD MILLION)
TABLE 290. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 291. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 292. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 293. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 294. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 295. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 296. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 297. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 298. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 299. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 300. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 301. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 302. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 303. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 304. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2017-2032 (USD MILLION)
TABLE 305. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2017-2032 (USD MILLION)
TABLE 306. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 307. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 308. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 309. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 310. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 311. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 312. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 313. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 314. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 315. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 316. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 317. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 318. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 319. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 320. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2017-2032 (USD MILLION)
TABLE 321. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2017-2032 (USD MILLION)
TABLE 322. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 323. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 324. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 325. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 326. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 327. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 328. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 329. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 330. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 331. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 332. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 333. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 334. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 335. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2017-2032 (USD MILLION)
TABLE 336. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2017-2032 (USD MILLION)
TABLE 337. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2017-2032 (USD MILLION)
TABLE 338. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 339. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 340. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 341. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 342. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 343. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 344. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 345. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2017-2032 (USD MILLION)
TABLE 346. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2017-2032 (USD MILLION)
TABLE 347. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 348. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 349. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 350. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 351. GCC INFECTIOUS D

Companies Mentioned

  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • bioMérieux SA
  • Boston Scientific Corporation
  • Bruker Corporation
  • Cardinal Health Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Grifols, S.A.
  • Hologic Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips N.V.
  • MedMira Inc.
  • Medtronic PLC
  • Merck KGaA
  • Olympus Corporation
  • Perkin Elmer, Inc.
  • Pfizer Inc.
  • Qiagen N.V.
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
  • Trivitron Healthcare

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 29.41 Billion
Forecasted Market Value ( USD ) by 2032 $ 49.28 Billion
Compound Annual Growth Rate8.9%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

North America Infectious Disease Diagnostics Market Forecast to 2030 - Regional Analysis - By Product, Technology, Application Type, Testing Type, and End User - Product Image

North America Infectious Disease Diagnostics Market Forecast to 2030 - Regional Analysis - By Product, Technology, Application Type, Testing Type, and End User

  • Report
  • 115 Pages
  • North America
From
Asia Pacific Infectious Disease Diagnostics Market Forecast to 2030 - Regional Analysis - By Product, Technology, Application Type, Testing Type, and End User - Product Image

Asia Pacific Infectious Disease Diagnostics Market Forecast to 2030 - Regional Analysis - By Product, Technology, Application Type, Testing Type, and End User

  • Report
  • 136 Pages
  • Asia Pacific
From
Infectious Disease Diagnostics - Global Strategic Business Report - Product Image

Infectious Disease Diagnostics - Global Strategic Business Report

  • Report
  • 756 Pages
  • Global
From
Infectious Diseases In-Vitro Diagnostics Market - Global Forecast 2026-2032 - Product Image

Infectious Diseases In-Vitro Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Healthcare-associated Infectious Disease Diagnostics Market - Global Forecast 2026-2032 - Product Image

Healthcare-associated Infectious Disease Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From

About the Infectious Disease Testing Market

The Infectious Disease Testing market is a sector of the healthcare industry that focuses on the diagnosis and treatment of infectious diseases. It includes a range of tests, such as blood tests, urine tests, and swab tests, to detect the presence of a pathogen. These tests are used to diagnose a wide range of infectious diseases, including HIV, hepatitis, and tuberculosis. The Infectious Disease Testing market is driven by the increasing prevalence of infectious diseases, the growing demand for rapid and accurate diagnosis, and the development of new technologies. Companies in this market are developing innovative tests and technologies to improve the accuracy and speed of diagnosis. Some of the major companies in the Infectious Disease Testing market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. These companies are investing in research and development to develop new tests and technologies to improve the accuracy and speed of diagnosis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.